瑞舒伐他汀对高血压患者血糖、血脂及超敏C反应蛋白水平的影响

徐卫东; 闵兆晗

doi:10.7619/jcmp.201307008

瑞舒伐他汀对高血压患者血糖、血脂及超敏C反应蛋白水平的影响

徐卫东¹,
闵兆晗²

1.
江苏省滨海县中医院内科,江苏盐城,224500;
2.
江苏省滨海县蔡桥中心医院内科,江苏盐城,224531

基金项目: 中国高校医学期刊临床专项资金

详细信息

中图分类号: R544.1
计量
- 文章访问数: 277
- HTML全文浏览量: 23
- PDF下载量: 6
出版历程
- 发布日期: 2013-06-12

Effects of rosuvastatin on the levels of blood glucose, blood lipid and hypersensitive C-reactive protein in patients with hypertension

XU Weidong¹,
MIN Zhaohan²

摘要

摘要: 目的探讨瑞舒伐他汀对高血压患者血糖、血脂及超敏C反应蛋白(hs-CRP)水平的影响.方法选择86例不伴有糖尿病的高血压患者,采用自身对照方法,在常规降压治疗的基础上加服瑞舒伐他汀.观察用药前及用药8周后空腹血糖(FBG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及hs-CRP的变化.结果本组患者治疗后TC、LDL-C及hs-CRP水平均较治疗前显著下降,而HDL-C水平却显著升高,治疗前后比较差异均有统计学意义(P＜0.05或P＜0.01)；本组患者治疗后FBG及HbA1c水平较治疗前略有所上升,但治疗前后比较差异无统计学意义(P＞0.05).结论对高血压合并高脂血症及高hs-CRP水平者加用瑞舒伐他汀,可显著降低TC、LDL-C及hs-CRP水平,升高HDL-C水平,降低心血管临床终点.
- 瑞舒伐他汀 /
- 高血压 /
- 血糖 /
- 血脂 /
- 超敏C反应蛋白 /
- 糖尿病

HTML全文

参考文献(13)

Banerjee Y. Is prolong use of statins associated with increase in the risk of diabetes [J]. Journal of the American College of Cardiology, 2013(9):989.

Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease [J]. Diabetologia, 2013(4):686.

《中国高血压防治指南修订》委员会. 中国高血压防治指南(2010) [J]. 中华心血管病杂志, 2011(7):579.doi: 10.3760/cma.j.issn.0253-3758.2011.07.002.

Selwyn A P. Antiatherosclerotic effects of stains:LDL versus non-LDL effects [J]. Cunt Atheroscler Rep, 2007(4):281.

Libby P. Inflammatory mechanisms:the molecular basis of inflammation and disease [J]. Nutrition Reviews, 2007, (12):S140.

Virdis A, Schiffrin E L. Vascular inflammation:a role in vascular disease in hypertension [J]. Curr Opin in Nephrol and Hypertens, 2003(2):181.

Jones P H, Davidson M H, Stein E A. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses [J]. American Journal of Cardiology, 2003(2):152.

Ray K K, Cannon C P, Cairns R. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial [J]. Journal of the American College of Cardiology, 2005(8):1417.

徐琴玉. 瑞舒伐他汀对高血压合并高脂血症患者超敏C反应蛋白及血脂的影响 [J]. 实用预防医学, 2010, (11):2264.doi: 10.3969/j.issn.1006-3110.2010.11.054.

Sattar N, Preiss D, Murray H M. Statinsand risk of incident diabetes:a collaborative meta-analysis of randomized statin trials [J]. The Lancet, 2010, (9716):735.

Preiss D, Seshasai S R, Welsh P. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:a meta-analysis [J]. Journal of the American Medical Association, 2011, (24):2556.

Izzo R, de Simone G, Trimarco V. Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk [J]. Nutrition Metabolism and Cardiovascular Diseases, 2013.S0939-4753(12)00258-X.

Ridker P M, Danielson E, Fonseca F A. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein [J]. New England Journal of Medicine, 2008, (21):2195.

施引文献

资源附件(0)

计量

文章访问数: 277
HTML全文浏览量: 23
PDF下载量: 6
被引次数: 0

瑞舒伐他汀对高血压患者血糖、血脂及超敏C反应蛋白水平的影响

计量

出版历程

Effects of rosuvastatin on the levels of blood glucose, blood lipid and hypersensitive C-reactive protein in patients with hypertension

计量

出版历程

目录